Author

A. Delaidelli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Assay:proteomics· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1

Frequent Co-Authors

P. H. Sorensen· 3 shared A. Banuelos· 2 shared C. L. Mackall· 2 shared E. Sotillo· 2 shared I. L. Weissman· 2 shared J. Huang· 2 shared J. Theruvath· 2 shared K. D. Marjon· 2 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

P. H. Sorensen

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

The EIF4EBP1 gene encoding 4EBP1 is transcriptionally upregulated by MYC and linked to shorter survival in medulloblastoma

L. Hruby, K. Scharov, A. Delaidelli, D. Picard, C. Dunham, O. Lewandowska, T. Reiff, M. Larcher, C. Pouponnot, P. H. Sorensen, B. Rotblat, G. Reifenberger, M. Remke, G. Leprivier

This study shows that EIF4EBP1 is upregulated by MYC in medulloblastoma and linked to poorer patient survival.

bioRxiv · Mar 6, 2024 · PreprintCancer Biology

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma

A. K. Weiner, A. B. Radaoui, M. Tsang, D. Martinez, S. Sidoli, K. L. Conkrite, A. Delaidelli, A. Modi, J. L. Rokita, K. Patel, M. V. Lane, B. Zhang, C. Zhong, B. Ennis, D. P. Miller, , S. J. Diskin

This study identifies DLK1 as a potential immunotherapeutic target in neuroblastoma through integrative proteomic, transcriptomic, and epigenomic analysis.

bioRxiv · Dec 6, 2023 · PreprintCancer Biology

Engineered CD47 protects T cells for enhanced antitumor immunity

S. A. Yamada-Hunter, J. Theruvath, B. J. McIntosh, K. A. Freitas, M. T. Radosevich, A. Leruste, S. Dhingra, N. Martinez-Velez, P. Xu, A. Delaidelli, M. H. Desai, Z. Good, L. Labanieh, C. W. Mount, Y. Chen, , C. L. Mackall

This paper engineers a CD47 variant to protect T cells from macrophage clearance, enhancing antitumor efficacy by combining T cell and macrophage activation.

bioRxiv · Jun 20, 2023 · PreprintBioengineering

Anti-GD2 antibody disrupts GD2:Siglec-7 interactions and synergizes with CD47 blockade to mediate tumor eradication

J. Theruvath, M. Menard, B. A. Smith, M. H. Linde, G. Coles, W. Wu, L. Kiru, A. Delaidelli, J. L. Silberstein, A. Banuelos, S. Dhingra, E. Sotillo, S. Heitzeneder, A. Tousley, J. Lattin, , R. G. Majzner

This study shows that combining anti-GD2 and anti-CD47 antibodies enhances anti-tumor responses by recruiting macrophages and disrupting the GD2:Siglec-7 interaction in GD2+ cancers.

bioRxiv · Mar 19, 2021 · PreprintImmunology